Singapore markets open in 6 hours 35 minutes

Tarsus Pharmaceuticals, Inc. (TARS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
35.67-1.68 (-4.51%)
As of 02:24PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close37.35
Open42.50
Bid29.56 x 200
Ask35.83 x 100
Day's range34.68 - 42.50
52-week range12.57 - 42.50
Volume1,048,844
Avg. volume696,740
Market cap1.347B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

    Generated $24.7 million in net product sales of XDEMVY®, an 89% increase over Q4 2023, and delivered approximately 26,000 bottles of XDEMVY to patients Secured multiple commercial payer contracts and remain on-track for broad commercial coverage by the end of 2024 and Medicare coverage beginning in 2025 Expanded sales force on-track to be in the field by the end of the third quarter 2024 Strengthened financial position with an approximately $108 million public equity offering and $200 million fi

  • GlobeNewswire

    Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

    IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1.30 p.m. PT / 4.30 p.m. ET on Wednesday, May 8, 2024 to report its first quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the

  • GlobeNewswire

    Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

    IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai